CORMEDIX INC. ADDED TO NASDAQ BIOTECHNOLOGY INDEX
CORMEDIX INC. ADDED TO NASDAQ BIOTECHNOLOGY INDEX
December 19, 2024
2024年12月19日
Berkeley Heights, NJ – December 19, 2024 – CorMedix Inc. (Nasdaq: CRMD), a biopharmaceutical company focused on developing and commercializing therapeutic products for life-threatening diseases and conditions, today announced it will be added to the Nasdaq Biotechnology Index (Nasdaq: NBI) (the "NBI"). CorMedix's addition to the NBI will become effective prior to the market open on Monday, December 23, 2024.
新澤西州伯克利高地 – 2024年12月19日 – CorMedix Inc.（納斯達克：CRMD），一家專注於開發和商業化治療危及生命的疾病和症狀的生物製藥公司，今天宣佈將被納入納斯達克生物技術指數（納斯達克：NBI）（"NBI"）。CorMedix被納入NBI的決定將於2024年12月23日星期一市場開盤前生效。
The NBI is designed to track the performance of a set of securities listed on The NASDAQ Stock Market (NASDAQ) that are classified as either biotechnology or pharmaceutical companies and is a modified market capitalization weighted index. The NBI is reconstituted annually in December in accordance with a set of eligibility criteria including minimum market capitalization and average daily trading volume, among other criteria.
NBI旨在跟蹤一組在納斯達克證券市場（納斯達克）上市的證券的表現，這些證券被分類爲生物技術或藥品公司，並且是一個修改後的市值加權指數。NBI每年在12月根據一套包括最低市值和平均每日成交量等資格標準進行重組。
For more information about the NBI, visit:
有關NBI的更多信息，請訪問：
About CorMedix
關於CorMedix
CorMedix Inc. is a biopharmaceutical company focused on developing and commercializing therapeutic products for the prevention and treatment of life-threatening conditions and diseases. The Company is focused on commercializing its lead product DefenCath (taurolidine and heparin) which was approved by the FDA on November 15, 2023. CorMedix commercially launched DefenCath in inpatient settings in April 2024 and in outpatient settings in July 2024. CorMedix also intends to develop DefenCath as a catheter lock solution for use in other patient populations. For more information visit: .
CorMedix Inc.是一家生物製藥公司，專注於開發和商業化用於預防和治療危及生命的疾病和病症的治療產品。公司專注於商業化其主要產品DefenCath（氟羅阿啶和肝素），該產品於2023年11月15日獲得FDA批准。CorMedix於2024年4月在住院環境中正式推出DefenCath，並於2024年7月在門診環境中推出。CorMedix還計劃將DefenCath開發爲用於其他患者人群的導管鎖定解決方案。有關更多信息，請訪問：.
Investor Contact:
Dan Ferry
Managing Director
LifeSci Advisors
投資者聯繫人：
Dan Ferry
常務董事
LifeSci顧問
daniel@lifesciadvisors.com
(617) 430-7576
daniel@lifesciadvisors.com
(617) 430-7576
譯文內容由第三人軟體翻譯。
